載入中
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
前收盤價
US$1.84
+US$0.06 · +3.37%
盤後
US$1.84
US$0.00 · 0.00%
10月7日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
日內區間
目前US$1.84
52週區間
目前US$1.84
盤中時間採用ET。市場資料可能有所延遲。
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
日內區間
目前US$1.84
52週區間
目前US$1.84
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9049.7萬 USD | 8378.9萬 USD | 6867.5萬 USD | 5366.2萬 USD | 4841.6萬 USD |
| 銷貨成本 | 2335.8萬 USD | 2178.8萬 USD | 1792.3萬 USD | 1379.7萬 USD | 1278.6萬 USD |
| 毛利 | 6713.9萬 USD | 6200.1萬 USD | 5075.2萬 USD | 3986.5萬 USD | 3563萬 USD |
| 研究與開發 | 1949.1萬 USD | 1757萬 USD | 1808萬 USD | 1539.7萬 USD | 1306.3萬 USD |
| 銷售、一般及管理費用 | 1.01億 USD | 1.02億 USD | 9460.7萬 USD | 8310.5萬 USD | 6987.1萬 USD |
| 營業費用 | 1.21億 USD | 1.2億 USD | 1.13億 USD | 9850.2萬 USD | 8293.4萬 USD |
| 利息收入 | 265.1萬 USD | 506.1萬 USD | 556.8萬 USD | 152.9萬 USD | 40萬 USD |
| 利息支出 | 315.5萬 USD | 350.7萬 USD | 323.2萬 USD | 106.6萬 USD | 82.9萬 USD |
| 折舊和攤銷 | 105.4萬 USD | 149.3萬 USD | 154.8萬 USD | 151.3萬 USD | 86.7萬 USD |
| 營業利益 | −5366.3萬 USD | −5770.4萬 USD | −6193.5萬 USD | −5863.7萬 USD | −4730.4萬 USD |
| 淨利 | −5400.3萬 USD | −5639.4萬 USD | −6084.3萬 USD | −5892.3萬 USD | −4866.1萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI274.24萬0.00%2.3兆 USD0.03%US$381.03-0.40%
Vanguard Extended Market ETFVXF119.73萬0.00%954億 USD0.05%US$233.49-1.56%
iShares Micro-Cap ETFIWC23.13萬0.02%13.33億 USD0.60%US$183.36-1.09%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6萬0.05%1.17億 USD0.73%US$15.97-0.38%
Avantis U.S. Small Cap Equity ETFAVSC2.38萬—30.76億 USD0.25%US$69.63-1.18%
U.S. Micro Cap Portfolio ETFDFMC2.21萬0.00%75.2億 USD0.43%US$57.50-1.29%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.01萬0.00%61.57億 USD0.26%US$67.96-0.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Micro Cap Portfolio ETFDFMCU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
